Jasper Therapeutics (JSPR) Preferred Stock Liabilities (2019 - 2021)
Jasper Therapeutics (JSPR) posted quarterly Preferred Stock Liabilities of $81.3 million for Q2 2021, up 1003.22% year-over-year from $7.4 million in Q2 2020, and down 4.21% quarter-over-quarter from $84.9 million in Q1 2021.
Jasper Therapeutics (JSPR) Preferred Stock Liabilities (2019 - 2021) Analysis & Trends
Jasper Therapeutics' Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $81.3 million for Q2 2021.
- In Q2 2021, Preferred Stock Liabilities rose 1003.22% year-over-year to $81.3 million; the TTM figure through Jun 2021 stood at $81.3 million (up 1003.22% YoY), while the FY2020 annual figure was $79.4 million, down 7.55% from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $81.3 million, down from $84.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $87.3 million in Q1 2020, with the low at -$9.0 million in Q2 2020.
- The 3-year median for Preferred Stock Liabilities is $82.0 million (2020), against an average of $70.2 million.
- The sharpest annual moves came in 2020 and 2021: Preferred Stock Liabilities declined 7.55% in 2020, then soared 1003.22% in 2021.
- Jasper Therapeutics' Preferred Stock Liabilities stood at $85.8 million in 2019, then slipped by 7.55% to $79.4 million in 2020, then increased by 2.43% to $81.3 million in 2021.
- Business Quant data shows JSPR's Preferred Stock Liabilities at $81.3 million in Q2 2021, $84.9 million in Q1 2021, and $79.4 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Jasper Therapeutics | 20.38 Mn | 20.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 81.29 Mn |
| Mar 31, 2021 | 84.86 Mn |
| Dec 31, 2020 | 79.36 Mn |
| Sep 30, 2020 | 81.98 Mn |
| Jun 30, 2020 | -9.00 Mn |
| Mar 31, 2020 | 87.27 Mn |
| Dec 31, 2019 | 85.84 Mn |